胃肠道诊断市场－全球产业规模、份额、趋势、机会及预测（依检测类型、技术、应用、检测地点、地区及竞争格局划分，2021-2031年）

全球胃肠道诊断市场预计将从 2025 年的 55.8 亿美元成长到 2031 年的 73.3 亿美元，复合年增长率为 4.65%。

此细分市场包括用于识别整个消化道（包括肠道、胃和食道）病变的专用检测试剂盒、影像技术和医疗检测平台。市场成长的根本驱动因素是全球人口老化导致临床筛检频率增加，以及功能性疾病和消化器官系统恶性肿瘤盛行率上升。这些驱动因素代表着对疾病监测和早期检测能力的持续结构性需求成长，使其有别于暂时的产业趋势。

根据美国癌症协会预测，2024年美国将新增约152,810例结直肠癌病例，鑑于该疾病负担沉重，精准诊断工具的紧迫性凸显。然而，由于分子检测设备和先进内视镜系统需要大量资金投入，市场扩张面临许多障碍。高成本限制了预算紧张的医疗机构使用这些设备，最终阻碍了这些先进诊断技术的广泛应用。

市场驱动因素

慢性胃肠道疾病和胃肠道癌症的日益普遍是全球胃肠道诊断市场的主要驱动力。胃癌、大肠直肠癌和胰臟癌等恶性肿瘤发病率的上升迫使医疗系统优先考虑早期检测以降低高死亡率，从而持续推动对先进影像技术和成熟内视镜设备的需求。例如，美国癌症协会发布的《2024年癌症事实与数据》报告显示，胰臟癌仍是一种高致死率的癌症，预计光是2024年美国就有51,750人死于胰臟癌。为了反映这一需求，Olympus Corporation在2024年5月发布报告称，其内视镜解决方案部门在截至2024年3月的财年销售额将达到5,866亿日元，证实了该公司对侵入性诊断工具的持续依赖。

同时，受居家和照护现场解决方案需求成长的驱动，市场正经历重大变革。支付方和患者越来越倾向于选择非侵入性筛检方法，例如粪便DNA检测。与传统大肠镜检查相比，粪便DNA检测具有更高的依从性和便利性，从而扩大了诊断覆盖范围，并惠及服务不足的人。这一转变对市场领导的财务表现产生了显着影响。 2024年2月，Exact Sciences公司报告称，筛检收入（主要得益于Cologuard检测）在2023财年增长了31%，达到18.7亿美元，这充分证明了非侵入性检测方案的商业性可行性。

市场挑战

胃肠道诊断市场成长面临的一大限制因素是先进分子检测仪器和内视镜系统所需的高额资本投入。医疗机构，尤其是注重成本控制的农村门诊部和社区医院，往往预算紧张，难以承担这些平台的高初始购置成本。因此，这些经济障碍迫使医疗机构长期使用老旧设备，延缓高通量技术的应用，且设备更换週期远远超出最佳临床需求，从根本上阻碍了检测量的成长。

日益收紧的报销环境进一步加剧了这种经济负担，降低了昂贵诊断设备的投资报酬率。例如，美国胃肠病学会 (ACG) 指出，在最终确定的 2025 年联邦医疗保险医师收费标准中，支付转换係数降低了 2.83%。这些报销率的降低直接侵蚀了胃肠病诊所的营运利润，并显着限制了它们投资高成本诊断设备的能力，阻碍了整个市场的成长。

市场趋势

将人工智慧 (AI) 整合到内视镜成像系统中，从根本上重新定义了胃肠道病变的检测标准。深度学习演算法现在可以在电脑辅助检测系统中即时分析影片串流，识别出人眼可能遗漏的息肉和病变，从而提高腺瘤检出率这一关键指标，并改善患者的治疗效果。这些自动化工具强大的临床疗效正在推动市场应用和监管核准。例如，FUJIFILM医疗保健美国公司于 2024 年 3 月宣布，其新核准的CAD EYE AI 系统与标准高清大肠镜检查相比，每次大肠镜检查的腺瘤检出率提高了 17%。

同时，市场正转向一次性内视镜，以简化复杂的再处理流程并降低交叉感染的风险。医院越来越多地在风险较高的手术中采用这些经过消毒的一次性设备，以确保病患安全并降低与清洁昂贵的可重复使用设备相关的营运成本。这种转变体现在一次性内视镜平台的快速商业性扩张上。 2024年11月，Amb A/S公司公布其内视镜解决方案部门2023/24财年的有机收入成长了19.7%，这反映了一次性内视镜迅速融入标准临床实务。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球胃肠道诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依检测类型（内视镜检查、血液检查、幽门螺旋桿菌检测、钙卫蛋白检测、免疫球蛋白A检测、其他）
  • 按技术（ELISA、PCR、微生物学、其他）
  • 依应用领域（感染疾病、发炎性肠道疾病、胃食道逆流、癌症等）
  • 按检测地点（中心检查室和照护现场）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美胃肠道诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲胃肠道诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区胃肠道诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲胃肠道诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲胃肠道诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球胃肠道诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• bioMerieux SA
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories, Inc.
• Beckman Coulter, Inc.
• DiaSorin SpA
• Siemens Healthineers AG
• QIAGEN NV
• Meridian Bioscience, Inc.
• Hologic, Inc.
• Epitope Diagnostics Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Gastrointestinal Diagnostics Market is projected to expand from USD 5.58 Billion in 2025 to USD 7.33 Billion by 2031, registering a CAGR of 4.65%. This sector comprises a specialized array of assay kits, imaging technologies, and medical testing platforms engineered to identify pathological conditions across the digestive tract, including the intestines, stomach, and esophagus. The market's growth is fundamentally anchored by an aging global population necessitating frequent clinical screening and the rising prevalence of functional disorders and gastrointestinal malignancies. These drivers represent a durable structural increase in the demand for disease monitoring and early detection capabilities, distinguishing them from temporary industry trends.

According to the American Cancer Society, approximately 152,810 new cases of colorectal cancer were anticipated to be diagnosed in the United States in 2024, highlighting the urgent need for accurate diagnostic tools given the high disease burden. However, market expansion faces a significant hurdle due to the substantial capital expenditures required for molecular testing equipment and advanced endoscopic systems. This high cost barrier restricts accessibility in budget-constrained healthcare environments, thereby limiting the broader adoption of these advanced diagnostic technologies.

Market Driver

The escalating prevalence of chronic digestive disorders and gastrointestinal cancers acts as the primary catalyst for the Global Gastrointestinal Diagnostics Market. As the incidence of malignancies like gastric, colorectal, and pancreatic cancers rises, healthcare systems are forced to prioritize early detection to lower high mortality rates, creating sustained demand for advanced imaging modalities and established endoscopic hardware. For example, the American Cancer Society's 'Cancer Facts & Figures 2024' noted that pancreatic cancer remains highly lethal, with an estimated 51,750 deaths expected in the U.S. alone that year. Reflecting this demand, Olympus Corporation reported in May 2024 that its Endoscopic Solutions Division achieved revenue of 586.6 billion JPY for the fiscal year ended March 31, 2024, confirming the continued reliance on invasive diagnostic tools.

Concurrently, the market is undergoing a significant transformation driven by the growing preference for at-home and point-of-care diagnostic solutions. Payers and patients are increasingly favoring non-invasive screening methods, such as stool-based DNA tests, which improve compliance and convenience compared to traditional colonoscopies, thus extending diagnostic reach to under-screened populations. This shift has notably impacted the financial performance of market leaders; Exact Sciences Corp. reported in February 2024 that its screening revenue, largely driven by Cologuard tests, grew by 31 percent to 1.87 billion USD for the full year 2023, demonstrating the commercial viability of non-invasive options.

Market Challenge

A major restraint on the growth of the gastrointestinal diagnostics market is the significant capital expense required for advanced molecular testing equipment and endoscopic systems. Healthcare facilities, particularly outpatient clinics and community hospitals in cost-sensitive areas, often operate with limited budgets that cannot support the high upfront procurement costs of these platforms. Consequently, these financial barriers force the prolonged use of legacy instrumentation and delay the adoption of higher-throughput technologies, leading to a structural deceleration in volume growth as equipment replacement cycles extend well beyond optimal clinical timelines.

This economic strain is further intensified by a contracting reimbursement landscape that reduces the return on investment for expensive diagnostic assets. For instance, the American College of Gastroenterology noted that the finalized 2025 Medicare Physician Fee Schedule included a 2.83 percent reduction in the payment conversion factor. Such cuts in reimbursement rates directly erode the operating margins of gastroenterology practices, severely limiting their financial capacity to invest in high-cost diagnostic capital equipment and thereby hindering the market's overall growth trajectory.

Market Trends

The integration of artificial intelligence into endoscopic imaging systems is fundamentally redefining detection standards for gastrointestinal pathologies. Deep learning algorithms are now utilized in computer-aided detection systems to analyze video feeds in real-time, identifying polyps and lesions that might otherwise be missed by human observation, thereby addressing the critical variable of adenoma detection rates and improving patient outcomes. The superior clinical efficacy of these automated tools is driving market adoption and regulatory clearances; for example, Fujifilm Healthcare Americas Corporation announced in March 2024 that its newly cleared CAD EYE AI system demonstrated a 17 percent higher adenoma per colonoscopy rate compared to standard high-definition colonoscopy.

Simultaneously, the market is shifting toward single-use disposable endoscopes to eliminate complex reprocessing workflows and mitigate cross-contamination risks. Hospitals are increasingly adopting these sterile, one-time-use devices for high-risk procedures to ensure patient safety and reduce the operational overhead associated with cleaning capital-intensive reusable equipment. This transition is evident in the rapid commercial expansion of disposable platforms; Ambu A/S reported in November 2024 that organic revenue for its Endoscopy Solutions division increased by 19.7 percent for the 2023/24 financial year, reflecting the accelerating integration of disposable scopes into standard clinical practice.

Key Market Players

• bioMerieux S.A.
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories, Inc.
• Beckman Coulter, Inc.
• DiaSorin S.p.A
• Siemens Healthineers AG
• QIAGEN N.V.
• Meridian Bioscience, Inc.
• Hologic, Inc.
• Epitope Diagnostics Inc.

Report Scope

In this report, the Global Gastrointestinal Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastrointestinal Diagnostics Market, By Test Type

• Endoscopy
• Blood Test
• H. pylori Test
• Calprotectin Test
• Immunoglobulin A Test
• and Others

Gastrointestinal Diagnostics Market, By Technology

• ELISA
• PCR
• Microbiology
• and Others

Gastrointestinal Diagnostics Market, By Application

• Infection
• Inflammatory Bowel Disease
• Gastroesophageal Reflux Disease
• Cancer
• and Others

Gastrointestinal Diagnostics Market, By Test Location

• Central laboratories and Point-of-Care

Gastrointestinal Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastrointestinal Diagnostics Market.

Available Customizations:

Global Gastrointestinal Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gastrointestinal Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Endoscopy, Blood Test, H. pylori Test, Calprotectin Test, Immunoglobulin A Test, and Others)
  • 5.2.2. By Technology (ELISA, PCR, Microbiology, and Others)
  • 5.2.3. By Application (Infection, Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Cancer, and Others)
  • 5.2.4. By Test Location (Central laboratories and Point-of-Care)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Gastrointestinal Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By Test Location
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gastrointestinal Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Test Location
  • 6.3.2. Canada Gastrointestinal Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Test Location
  • 6.3.3. Mexico Gastrointestinal Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Test Location

7. Europe Gastrointestinal Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By Test Location
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gastrointestinal Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Test Location
  • 7.3.2. France Gastrointestinal Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Test Location
  • 7.3.3. United Kingdom Gastrointestinal Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Test Location
  • 7.3.4. Italy Gastrointestinal Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Test Location
  • 7.3.5. Spain Gastrointestinal Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Test Location

8. Asia Pacific Gastrointestinal Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By Test Location
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gastrointestinal Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Test Location
  • 8.3.2. India Gastrointestinal Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Test Location
  • 8.3.3. Japan Gastrointestinal Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Test Location
  • 8.3.4. South Korea Gastrointestinal Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Test Location
  • 8.3.5. Australia Gastrointestinal Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Test Location

9. Middle East & Africa Gastrointestinal Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By Test Location
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gastrointestinal Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Test Location
  • 9.3.2. UAE Gastrointestinal Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Test Location
  • 9.3.3. South Africa Gastrointestinal Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Test Location

10. South America Gastrointestinal Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By Test Location
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gastrointestinal Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Test Location
  • 10.3.2. Colombia Gastrointestinal Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Test Location
  • 10.3.3. Argentina Gastrointestinal Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Test Location

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gastrointestinal Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. bioMerieux S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Abbott Laboratories, Inc.
• 15.4. Beckman Coulter, Inc.
• 15.5. DiaSorin S.p.A
• 15.6. Siemens Healthineers AG
• 15.7. QIAGEN N.V.
• 15.8. Meridian Bioscience, Inc.
• 15.9. Hologic, Inc.
• 15.10. Epitope Diagnostics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer